炎症性腸疾患に対する腹部ターゲット型運動療法の治療的介入
Lael Werner1, Rony Izhar1, Morine Fibelman1
1IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Medical Center, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel.
Journal of science and medicine in sport
|December 30, 2025
まとめ
腹部ターゲット型運動は炎症性腸疾患(IBD)患者の臨床転帰を改善し、バイオマーカーを安定させたが、特にクローン病患者で顕著であった。一般的な運動も有益性を示したが、ターゲット型運動ほど顕著ではなかった。
科学分野:
- 消化器病学
- 運動生理学
- 免疫学
背景:
- 炎症性腸疾患(IBD)の管理には、しばしば薬物療法や生活習慣の調整が含まれる。
- 特定の運動(PhExs)のIBDにおける役割は、新たな研究分野である。
- 腹部集中型運動は、腸の健康や炎症に影響を与える可能性がある。
研究 の 目的:
- IBD患者における腹部ターゲット型運動と一般的な運動の効果を、臨床転帰、バイオマーカー、QOL(Quality of Life)について比較すること。
- 特定の運動レジメンによる4週間の介入の影響を評価すること。
主な方法:
- 26人のIBD患者(クローン病[CD]15人、潰瘍性大腸炎[UC]11人)を対象としたランダム化、対照、二重盲検パイロット研究。
- 参加者は4週間、毎日15分間のビデオガイド付き運動を行った:腹部ターゲット型運動または一般的な運動。
- 疾患活動性、炎症マーカー(CRP、便中カルプロテクチン)、QOL(PROMIS-29)を測定した。
主要な成果:
- 両運動群ともに臨床的改善が見られたが、ターゲット型運動群のクローン病患者は有意に高い寛解率(75% vs 14%)を達成した。
- ターゲット型運動群では便中カルプロテクチン値が安定したが、一般的な運動群では増加した。
- QOL指標は改善したが、腹部ターゲット型運動のみに特異的に関連するものではなかった。
結論:
- 毎日の腹部ターゲット型運動は、IBD、特にクローン病患者における臨床的改善とバイオマーカー安定化の可能性を示す。
- 本研究結果は、IBD管理における腹部活性化運動の特異的な利点を強調する。
- これらの予備的結果を確認するためには、より大規模なサンプルサイズとより長期間の研究が必要である。
関連する概念動画
Inflammatory Bowel Disease V: Surgical Management
423
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
423
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
609
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
609
Inflammatory Bowel Disease IV: Pharmacological Management
439
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
439
Drugs for Treatment of Ulcerative Colitis in IBD
416
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
416
Drugs for Treatment of Constipation-Predominant IBS
670
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
670
Drugs for Treatment of Diarrhea-Predominant IBS
593
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
593


